China Pharma Industry Braces For Environmental Protection Regulations
This article was originally published in PharmAsia News
The State Environmental Protection Administration of China published an online draft on the discharge standard of pollutants for the pharmaceutical industry last October to solicit feedback. This, and a catalog on high-pollution and high-risk products, are expected to be rolled out next year. Analysts observe that an enterprise will face more difficulty implementing the new environmental standards than getting a national good manufacturing practises authentication as additional measures greatly increase production costs. Local environmental protection expenses are as high as 350 million yuan for Shijiazhuang Pharmaceutical Group Co. Ltd. The new regulations will put pressure on the pharmaceutical industry, and the government is looking at green tax policies to provide incentives for environmental investment. (Click here for more)
You may also be interested in...
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.